{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:37:16Z","timestamp":1775237836420,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ejphar.2022.174898","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T21:33:42Z","timestamp":1647466422000},"page":"174898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["9-Nitro-20(S)-carbonate-camptothecin (NCP4), a novel prodrug of 9-nitrocamptothecin (9-NC), exhibits potent chemotherapeutic efficacy and improved safety against hepatocarcinoma"],"prefix":"10.1016","volume":"923","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5852-3953","authenticated-orcid":false,"given":"Hongyu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Qing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.174898_bib1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0360-3016(00)00461-2","article-title":"Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20(S)-camptothecin) as a radiation enhancer","volume":"47","author":"Amorino","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejphar.2022.174898_bib2","first-page":"3026","article-title":"Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks","volume":"8","author":"Avemann","year":"1988","journal-title":"Mol. Cell Biol."},{"issue":"Suppl. 4","key":"10.1016\/j.ejphar.2022.174898_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1634\/theoncologist.6-suppl_4-12","article-title":"Answering patients' needs: oral alternatives to intravenous therapy","volume":"6","author":"Borner","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.ejphar.2022.174898_bib4","first-page":"336","article-title":"Synergistic antitumor activity of capecitabine in combination with irinotecan","volume":"4","author":"Cao","year":"2005","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.ejphar.2022.174898_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0378-4347(98)00270-9","article-title":"Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography","volume":"718","author":"Chollet","year":"1998","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.ejphar.2022.174898_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0304-4165(96)00113-4","article-title":"Structure-activity relation in camptothecin antitumor drugs: why a detailed molecular characterisation of their lactone and carboxylate forms by Raman and SERS spectroscopies?","volume":"1334","author":"Chourpa","year":"1997","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2022.174898_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0304-4165(97)00115-3","article-title":"Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy","volume":"1379","author":"Chourpa","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2022.174898_bib8","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0960-894X(02)00388-8","article-title":"Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin","volume":"12","author":"de Groot","year":"2002","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2022.174898_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejpb.2006.09.004","article-title":"Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics","volume":"66","author":"Derakhshandeh","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejphar.2022.174898_bib10","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s11095-010-0130-x","article-title":"Phospholipids and lipid-based formulations in oral drug delivery","volume":"27","author":"Fricker","year":"2010","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejphar.2022.174898_bib11","doi-asserted-by":"crossref","DOI":"10.1088\/1748-6041\/3\/1\/015013","article-title":"Controlled release of 9-nitro-20(S)-camptothecin from methoxy poly(ethylene glycol)-poly(D,L-lactide) micelles","volume":"3","author":"Gao","year":"2008","journal-title":"Biomed. Mater."},{"key":"10.1016\/j.ejphar.2022.174898_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1166\/jbn.2016.2144","article-title":"In vitro and in vivo therapeutic evaluation of camptothecin-encapsulated beta-cyclodextrin nanosponges in prostate cancer","volume":"12","author":"Gigliotti","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ejphar.2022.174898_bib13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1590\/S0100-879X2001000900001","article-title":"Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer","volume":"34","author":"Grivicich","year":"2001","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.ejphar.2022.174898_bib14","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1023\/A:1020427227285","article-title":"Camptothecin delivery methods","volume":"19","author":"Hatefi","year":"2002","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejphar.2022.174898_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/B:DRUG.0000006176.84915.71","article-title":"A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer","volume":"22","author":"Miller","year":"2004","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejphar.2022.174898_bib16","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1021\/ja00968a057","article-title":"Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata1,2","volume":"88","author":"Monroe","year":"1966","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejphar.2022.174898_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1021\/np030498t","article-title":"Camptothecin and taxol: historic achievements in natural products research","volume":"67","author":"Oberlies","year":"2004","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejphar.2022.174898_bib18","article-title":"Lesser toxicities of belotecan in patients with small cell lung cancer: a retrospective single-center study of camptothecin analogs","author":"Park","year":"2016","journal-title":"Can. Respir. J."},{"key":"10.1016\/j.ejphar.2022.174898_bib19","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0959-8049(02)00070-9","article-title":"Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme","volume":"38","author":"Raymond","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2022.174898_bib20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0163-7258(95)02009-8","article-title":"Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives","volume":"68","author":"Rivory","year":"1995","journal-title":"Pharmacol. Ther."},{"issue":"Suppl. 6","key":"10.1016\/j.ejphar.2022.174898_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1634\/theoncologist.9-90006-33","article-title":"Topotecan in the first-line treatment of small cell lung cancer","volume":"9","author":"Stewart","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.ejphar.2022.174898_bib22","first-page":"291","article-title":"Patient preferences for chemotherapy schedules used in the treatment of advanced colorectal cancer--a pilot study","volume":"6","author":"Topham","year":"1997","journal-title":"Eur. J. Cancer Care"},{"key":"10.1016\/j.ejphar.2022.174898_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00001813-199801000-00004","article-title":"A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor","volume":"9","author":"Verschraegen","year":"1998","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejphar.2022.174898_bib24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1349-7006.1993.tb00177.x","article-title":"DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells","volume":"84","author":"Yoshida","year":"1993","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.ejphar.2022.174898_bib25","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1080\/17425247.2021.1928631","article-title":"Fabrication of versatile targeted lipopolymersomes for improved camptothecin efficacy against colon adenocarcinoma in vitro and in vivo","volume":"18","author":"Zahiri","year":"2021","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.ejphar.2022.174898_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1734-1140(13)70959-9","article-title":"Prodrugs: a challenge for the drug development","volume":"65","author":"Zawilska","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2022.174898_bib27","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1021\/jo000221n","article-title":"20-O-acylcamptothecin derivatives: evidence for lactone stabilization","volume":"65","author":"Zhao","year":"2000","journal-title":"J. Org. Chem."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922001595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922001595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:01:43Z","timestamp":1757977303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922001595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":27,"alternative-id":["S0014299922001595"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.174898","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"9-Nitro-20(S)-carbonate-camptothecin (NCP4), a novel prodrug of 9-nitrocamptothecin (9-NC), exhibits potent chemotherapeutic efficacy and improved safety against hepatocarcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.174898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"174898"}}